Stoke Therapeutics (STOK) Cash & Current Investments (2018 - 2026)

Stoke Therapeutics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $343.5 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 3.86% year-over-year to $343.5 million in Q1 2026; TTM through Mar 2026 was $343.5 million, a 3.86% decrease from a year earlier, with the FY2025 full-year figure at $284.7 million, up 31.25% from the prior year.
• Cash & Current Investments advanced to $343.5 million in Q1 2026 per STOK's latest filing, from $284.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $357.3 million in Q1 2025 and bottomed at $150.1 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $247.7 million (2025), against an average of $245.4 million.
• Across the five-year window, Cash & Current Investments slumped 30.1% in 2024 and jumped 100.09% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $229.6 million in 2022, then slipped by 12.28% to $201.4 million in 2023, then climbed by 7.7% to $216.9 million in 2024, then jumped by 31.25% to $284.7 million in 2025, then advanced by 20.68% to $343.5 million in 2026.
• Per Business Quant, the three latest STOK Cash & Current Investments figures stand at $343.5 million (Q1 2026), $284.7 million (Q4 2025), and $248.3 million (Q3 2025).